- Home
- ADPT vs AWF Comparison
ADPT vs AWF Comparison
Compare ADPT & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- AWF
- Stock Information
- Founded
- ADPT 2009
- AWF 1993
- Country
- ADPT United States
- AWF United States
- Employees
- ADPT N/A
- AWF N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- AWF Trusts Except Educational Religious and Charitable
- Sector
- ADPT Health Care
- AWF Finance
- Exchange
- ADPT Nasdaq
- AWF Nasdaq
- Market Cap
- ADPT 1.1B
- AWF 928.7M
- IPO Year
- ADPT 2019
- AWF N/A
- Fundamental
- Price
- ADPT $7.43
- AWF $10.74
- Analyst Decision
- ADPT Strong Buy
- AWF
- Analyst Count
- ADPT 5
- AWF 0
- Target Price
- ADPT $9.40
- AWF N/A
- AVG Volume (30 Days)
- ADPT 2.2M
- AWF 190.0K
- Earning Date
- ADPT 05-06-2025
- AWF 01-01-0001
- Dividend Yield
- ADPT N/A
- AWF 7.57%
- EPS Growth
- ADPT N/A
- AWF N/A
- EPS
- ADPT N/A
- AWF N/A
- Revenue
- ADPT $178,957,000.00
- AWF N/A
- Revenue This Year
- ADPT $21.21
- AWF N/A
- Revenue Next Year
- ADPT $21.98
- AWF N/A
- P/E Ratio
- ADPT N/A
- AWF N/A
- Revenue Growth
- ADPT 5.10
- AWF N/A
- 52 Week Low
- ADPT $2.28
- AWF $9.20
- 52 Week High
- ADPT $9.01
- AWF $10.67
- Technical
- Relative Strength Index (RSI)
- ADPT 44.19
- AWF 45.59
- Support Level
- ADPT $6.92
- AWF $10.74
- Resistance Level
- ADPT $9.01
- AWF $10.84
- Average True Range (ATR)
- ADPT 0.57
- AWF 0.09
- MACD
- ADPT -0.01
- AWF 0.01
- Stochastic Oscillator
- ADPT 24.58
- AWF 73.75
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About AWF Alliancebernstein Global High Income Fund
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in the debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.